The value of personalised medicines for healthcare systems in Europe
The value of personalised medicines for healthcare systems in Europe
Highlights from WIN 2019
Goals of the WIN Consortium
Rapidly changing landscape of precision medicine in Japan
Optimising patient enrolment and efficacy of precision oncology clinical trials
Implementing national cancer control plans
Tackling the increase in cancer cases worldwide
Getting high level care to low and middle income countries
How will ASCO combat cancer disparities?
CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy
Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy for MM
ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low-dose dexamethasone